According to SPER Market Research, the Global Contraceptives Market is estimated to reach USD 20.27 billion by 2030 with a CAGR of 5.9%.
Oral contraceptive tablets, topical contraceptives, injectables, vaginal rings, condoms, contraceptive sponges, subdermal implants, and intrauterine devices are the primary product categories of contraceptives. Oral contraceptive pills are birth control or contraceptive tablets used to avoid pregnancy. It contains hormones that stop the ovaries from releasing eggs.
The need for contraceptives is being driven by the increase in sexually transmitted infections and disorders. Infections known as sexually transmitted diseases (STDs) are passed from one individual to another through sexual activity. The most frequent forms of close physical contact include anal, oral, and vaginal sex, although it can also spread through other means. The most typical way that STDs like herpes and HPV spread is through skin-to-skin contact. The spread of these diseases is halted by the use of contraceptives.
As the market for contraceptives grows in popularity, technology innovation is a major trend. The most recent development in the market for contraceptives is the use of digital methods. Tracking periods online allows users to determine which days are most likely to result in pregnancy.
Hormonal contraception therapy includes the oral contraceptive pill. These medications frequently cause side effects, which might vary from person to person. Birth control pill use over an extended period of time is associated with side effects such as bleeding, headaches, nausea, and weight gain. Numerous studies have been published to highlight the birth control tablets' long-term harmful consequences. Anxiety over using these long-term contraceptive tablets results from a lack of understanding while using them. Additionally, the limited adoption and acceptance of contraceptive methods are attributed in underdeveloped nations to the social shame associated with their usage as well as the high cost of these methods and tablets.
Impact of COVID-19 on the Global Contraceptives market:
In many different parts of the world, the COVID-19 pandemic has had an impact. To slow the pandemic's quick spread, governments all around the world put in place stringent lockdown procedures and social segregation standards. During the pandemic's early phases, manufacturing plants all around the world were shut down. The commercial launch of the healthcare sector may also be significantly delayed as a result of the economic crisis that followed the pandemic. Since the epidemic began in 2020, small and medium-sized businesses, which make up the backbone of technology providers, have seen a sharp decline in revenue. As a result of the supply chain disruptions that were noticed, market participants faced several difficulties. The second part of 2022 will see improvements though as new supplies come online.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Age group, By Product, By Distribution
|
| Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Agile Therapeutics, Allergan PLC., Bayer AG, GalaxoSmithKline PLC., Johnson & Johnson, Mylan N.V., Mankind Pharma, Novartis AG, Piramal Healthcare, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.
|
Global Contraceptives market, By Age group:
Based on the Age group, Global Contraceptives market is segmented as; 15-24 Years, 25-34 Years, 35-44 Years, 44 Years.
Global Contraceptives market, By Product:
Based on the Product, Global Contraceptives market is segmented as; Oral Contraceptive Pills, Intra-Uterine Devices, Contraceptive Sponges, Subdermal Implants, Vaginal Rings, Condoms, Topical Contraceptives, Injectables, Diaphragms.
Global Contraceptives market, By Distribution:
Based on the Distribution, Global Contraceptives market is segmented as; Hospitals Pharmacies, Online Pharmacies, Independent Pharmacies, Clinics, Others.
Global Contraceptives market, By Region:
The Global Contraceptives market is majorly driven by North-America. During the projected period, Asia-Pacific is anticipated to have the quickest rate of growth in the worldwide Global Contraceptives market.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Contraceptives market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Contraceptives Market, By Age Group, 2019-2030 (USD Million)
6.1. 15-24 Years
6.2. 25-34 Years
6.3. 35-44 Years
6.4. 44 Years
7. Global Contraceptives Market, By Product, 2019-2030 (USD Million)
7.1. Oral Contraceptive Pills
7.2. Intra-Uterine Devices
7.3. Contraceptive Sponges
7.4. Subdermal Implants
7.5. Vaginal Rings
7.6. Condoms
7.7. Topical Contraceptives
7.8. Injectables
7.9. Diaphragms
8. Global Contraceptives Market, By Distribution, 2019-2030 (USD Million)
8.1. Hospital Pharmacies
8.2. Online Pharmacies
8.3. Independent Pharmacies
8.4. Clinics
8.5. Others
9. Global Contraceptives Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. Agile Therapeutics
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Allergan PLC.
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Bayer AG
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. GalaxoSmithKline PLC
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Johnson & Johnson
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Mylan N.V.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Mankind Pharma
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Novartis AG
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Piramal Healthcare
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Pfizer Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Sun Pharmaceutical Industries Ltd.
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Teva Pharmaceutical Industries Ltd.
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments